Bellaria Hospital, Bologna
Gemcitabine plus oxaliplatin used as first-line chemotherapy
Published in Drug Law Weekly, August 30th, 2005
"This phase II study evaluated the response rate and tolerability of gemcitabine-oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg/m2 on days 1 and 8, followed by oxaliplatin 130 mg/m2 on day 1," scientists in Italy reported.
"Cycles were repeated every 21 days for up to six cycles. From February 2002 to May 2004, 60 patients were enrolled into the study in seven Italian institutions. We observed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2005-08-30)
More Articles from Drug Law Weekly
- Abiomed, Inc.
Medical device firm reports 13% increase in revenues, clinical update - Catalyst Biosciences, Inc.
Intellectual property in the field of protease therapeutics licensed - CryoLife, Inc.
Biomaterials company reports that Q2 revenues increased 12% - Diomed Holdings, Inc.
Company responds to VNUS allegations - Inst. of Criminalistics & Criminology, Brussels
Method to measure delta9-tetrahydrocannabinol in oral fluid developed - Kline & Co.
Study: Generic drug makers taking more aggressive approach - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
